GLG News in Healthcare
August 18, 2008
Electronic Medical Records-EMR
Analysis of: Majority of Patients Want Doc to use EHRs: Study | www.modernhealthcare.com
Author: GLG Expert Contributor
Analysis of: Majority of Patients Want Doc to use EHRs: Study | www.modernhealthcare.com
Author: GLG Expert Contributor
Electronic Medical Records (EMR) or Electronic Health Records (EHR) are the most modern formats emerging in the medical field thanks to the innovations emerging in Information Technology Segment. Most of the current day patients are aware of medical attention needs unlike the olden past. However, the nuances of EMR are yet to be propagated by the medical fraternity or by the providers as such...
August 18, 2008
Agreement with Abbott will help Crestor sales
Analysis of: Abbott signs deal to promote Crestor in U.S. | www.chicagotribune.com
Author: GLG Expert Contributor
Analysis of: Abbott signs deal to promote Crestor in U.S. | www.chicagotribune.com
Author: GLG Expert Contributor
The co-marketing with Abbott will undoubtedly help Crestor sales, if they can effectively develop a fenofibrate-rosuvastatin combination, and avoid over-burdening physicians with reps. However, there are other factors that will probably have a larger impact.
August 18, 2008
30:70 chance of approval
Analysis of: AstraZeneca and Bristol-Myers Squibb Submit New Drug Application in the United States and Marketing Authorisation Application in Europe for ONGLYZA™ (Saxagliptin) for the Treatment of Type 2 Diabetes | www.astrazeneca.com
Author: GLG Expert Contributor
Analysis of: AstraZeneca and Bristol-Myers Squibb Submit New Drug Application in the United States and Marketing Authorisation Application in Europe for ONGLYZA™ (Saxagliptin) for the Treatment of Type 2 Diabetes | www.astrazeneca.com
Author: GLG Expert Contributor
Given what happened to Galvus, and the similar poor selectivity of saxagliptin for DPP-4 over other isoforms, I think that FDA approval is unlikely. There was also some data on changes in white count presented at the ADA that will hurt this agent. The FDA move to recommend outcome studies for DM treatments may also hurt them.
August 18, 2008
Promising start but more data needed
Analysis of: Lilly Diabetes Drug Shows a Life-Extending Promise | www.nytimes.com
Author: GLG Expert Contributor
Analysis of: Lilly Diabetes Drug Shows a Life-Extending Promise | www.nytimes.com
Author: GLG Expert Contributor
This will probably help Byetta sales modestly. However, the numbers ere small, it was a non-randomized comparison, and may be that Byetta use was a surrogate for less sulfonurea use, lower doses of insulin or no insulin at all (any of which may be harmful). However, the main barrier to more widespread Byetta use is the need for BID injections and the training required. These data may provide more...
August 15, 2008
Less and less evidence to favor coronary stenting
Analysis of: Heart Stents No Better Than Drugs for Chest Pain Over Time | www.bloomberg.com
Author: GLG Expert Contributor
Analysis of: Heart Stents No Better Than Drugs for Chest Pain Over Time | www.bloomberg.com
Author: GLG Expert Contributor
This study pretty convincingly shows that there is only a short term symptom and quality of life improvement associated with coronary stenting, as compared to good quality pharmacological treatment. This will decrease the pressure for aggressive revascularization of any and all coronary lesions (which has been pushed by many interventionalists). If the results are accepted by the health...
August 15, 2008
BiovaxID: Does It Work?
Analysis of: Biovest Reports Results for Patients Treated with Anti-Cancer Vaccine: BiovaxID(R) Demonstrates Clinically and Statistically Significant Improvement of Disease-Free Survival in Non-Hodgkin's Lymphoma in Pivotal Phase 3 Clinical Trial | biz.yahoo.com
Author: Donald Tsai, Assistant Professor of Medicine, University of Pennsylvania Cancer Center
BiovaxID: Does It Work?
Analysis of: Biovest Reports Results for Patients Treated with Anti-Cancer Vaccine: BiovaxID(R) Demonstrates Clinically and Statistically Significant Improvement of Disease-Free Survival in Non-Hodgkin's Lymphoma in Pivotal Phase 3 Clinical Trial | biz.yahoo.com
Author: Donald Tsai, Assistant Professor of Medicine, University of Pennsylvania Cancer Center
1) BiovaxID shows a 100% improvement in DFS at 3 years (p=0.24) 2) BiovaxID shows an improvement in median overall DFS with a significant P value (p=0.047) 2) This is the first lymphoma vaccine with a suggestion of activity. 3) BiovaxID shows evidence of activity despite the failure of 2 other lymphoma vaccines made by Genitiope and Favrille.
August 15, 2008
Byetta - what needs to be done
Analysis of: Lilly Diabetes Drug Shows a Life-Extending Promise | www.nytimes.com
Author: GLG Expert Contributor
Analysis of: Lilly Diabetes Drug Shows a Life-Extending Promise | www.nytimes.com
Author: GLG Expert Contributor
Very interesting results; Need more information. Did Janumet also result in weight loss? does weight loss disappear after a while? Was weight loss associated with an improvement in cardiovascular hemodynamics, lipid profile and elasticity of blood vessels; it will be interesting to see if the secondary features of diabetes mellitus will also be eliminated with Byetta. it will be interesting also to...
August 15, 2008Astra-Zeneca and Abbott partner on promoting Crestor..should Pfizer beware?
Analysis of: Abbott signs deal to promote Crestor in U.S. | www.chicagotribune.com
Author: Joseph Bertino, Independent Consultant, Bertino Consulting
-Crestor sold 2.8 billion dollars in sales in the recent year, will this partnership result in long term exponential growth? -What are the implications for Crestor with generic simvastatin and with Lipitor going generic in the next few years? -Is a combination product going to bolster Crestor sales?
August 14, 2008
Imaging and therapeutic agents for Brain tumor ( glioblastoma multiforme)
Analysis of: Recent Popular New Reports About Senator Ted Kennedy's Brain Tumor | www.cnn.com
Author: GLG Expert Contributor
Analysis of: Recent Popular New Reports About Senator Ted Kennedy's Brain Tumor | www.cnn.com
Author: GLG Expert Contributor
1. Public awareness and budget for research for brain will increase. 2. Federal funding should increase for GBM ( Glioblastoma multiforme) 3. More researchers will join in this field
August 14, 2008UK the model for US healthcare?
Analysis of: UK Says Kidney Cancer Drugs Are Too Pricey | www.pharmalot.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
In this election year some have encouraged adoption of socialized medical services UK healthcare is an example of what some in this country have said we need to model our future healthcare system The recent use of biologics such as the TKIs have resulted in options for thousands of advanced kidney cancer patients that would otherwise die of the illness UK says no to expensive...
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
FDA Alert: Hemorrhagic or Necrotizing Pancreatitis in Patients Taking Byetta
www.fda.gov
Healthways' Guidance Not So Healthy
www.forbes.com
Abbott signs deal to promote Crestor in U.S.
www.chicagotribune.com
Drug Makers’ Push Leads to Cancer Vaccines’ Fast Rise
www.nytimes.com
Hospital Death Rates Unveiled for First-Time Comparison
www.usatoday.com
Its all about the spin
August 21, 2008
Byetta sale will reduce after FAD alert
August 19, 2008
PCI numbers will not drop after Courage
August 19, 2008
Bad News (but not new news) for stents.
August 19, 2008
Less and less evidence to favor coronary stenting
August 15, 2008

